|
- Gilteritinib induces differentiation in relapsed and refractory
Biopsy of the rashes confirmed neutrophilic infiltrates (Sweet syndrome–like), 12 consistent with a prior study in which neutrophils purified from a skin biopsy specimen after FLT3 inhibitor treatment were shown to harbor FLT3 mutations 13 Together, these data are supportive of gilteritinib-induced differentiation of leukemic blasts Figure 1
- DIFFERENTIATION SYNDROME AFTER GILTERITINIB: A TRICKY MIMICKER OF . . .
Gilteritinib was then stopped and dexamethasone started Oxygen requirement decreased and she was discharged on day 6 with 3lpm nasal cannula DISCUSSION: DS, formerly known as retinoic acid syndrome, is a life-threatening reaction to differentiating agents used in the treatment of AML and APL
- Differentiation syndrome associated with treatment of acute . . . - UpToDate
Differentiation syndrome (DS; originally called "retinoic acid syndrome") is a potentially fatal complication of treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and or arsenic trioxide, treatment of acute myeloid leukemia (AML) with inhibitors of isocitrate dehydrogenase (IDH; ie, enasidenib, ivosidenib
- Management of toxicities associated with targeted therapies for acute . . .
Gilteritinib is linked to 2 severe but rare complications Differentiation syndrome (DS; 3%) may occur as early as 2 days and as late as 75 days after drug initiation and has been reported with several FLT3 inhibitors 14 Symptoms include fever, shortness of breath, rapid weight gain, new pleural and or pericardial effusions, heart failure, and
- Gilteritinib Differentiation Syndrome - Acibadem Health Point . . .
Gilteritinib Differentiation Syndrome When it comes to the treatment of acute myeloid leukemia (AML), targeted therapies have revolutionized patient care One such therapy is gilteritinib, a FLT3 inhibitor that has shown promising results in inhibiting the growth of leukemia cells However, as with any treatment, there can be potential side
- Myelomonocytic differentiation of leukemic blasts accompanied by . . .
Gilteritinib is a FLT3 inhibitor that inhibits both FLT3-ITD and FLT3-TKD It was reported that differentiation of leukemic blasts accompanied by differentiation syndrome occurs in some patients treated with gilteritinib
- XOSPATA® (gilteritinib) | Official Patient Site
XOSPATA may cause serious side effects including Differentiation Syndrome Differentiation Syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated Differentiation Syndrome can happen as early as 1 day after starting XOSPATA and during the first 3 months of treatment
- GILTERITINIB
Other clinical significant serious adverse reactions included differentiation syndrome, QT prolongation and posterior reversible encephalopathy syndrome (PRES)
|
|
|